Drug Trial Radar · NCT00958438
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
248
Actual
Start
Jul 2009
Primary completion
Dec 2010
Study completion Dec 2010
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Aug 13, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who are beginning allopurinol treatment for gout. Participants will participate in this study for approximately 22 weeks. Rilonacept was being studied for use in preventing allopurinol-induced gout flares.
Conditions
- Gout
Interventions
PlaceboDrug
Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
RilonaceptDrug
Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
RilonaceptDrug
Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16)Time frame: Day 1 to Day 113 (Week 16)
Locations
61 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Berlin, Germany
Site not named
Essen, Germany
Site not named
Goch, Germany
Site not named
Hamburg, Germany
Site not named
Kassel, Germany
Site not named
Künzing, Germany
Site not named
Lollar, Germany
Site not named
Magdeburg, Germany
Site not named
München, Germany
Site not named
Rhaunen, Germany
Site not named
Siegen, Germany
Site not named
Ahmedabad, India
Site not named
Bangalore, India
Site not named
Gandhinagar, India
Site not named
Hyderabaad, India
Site not named
Kolkata, India
Site not named
Mangalore, India
Site not named
Pune, India
Site not named
Secunderabad, India
Site not named
Vadodara, India
Site not named
Varanasi, India
Site not named
Denpasar, Indonesia
Site not named
Jakarta, Indonesia
Site not named
Kemerdekaan, Indonesia
Site not named
Palembang, Indonesia
Site not named
Semarang, Indonesia
Site not named
South Sulawesi, Indonesia
Site not named
West Java, Indonesia
Site not named
Yogyakarta, Indonesia
Site not named
Benoni, South Africa
Site not named
Bloemfontein, South Africa
Site not named
Breyten, South Africa
Site not named
Cape Town, South Africa
Site not named
Dundee, South Africa
Site not named
Durban, South Africa
Site not named
Durban North, South Africa
Site not named
eManzimtoti, South Africa
Site not named
Gauteng, South Africa
Site not named
Johannesburg, South Africa
Site not named
Kempton Park, South Africa
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.